What is Abselion?
Founded in 2018 as HexagonFab at the University of Cambridge, Abselion's mission is to simplify protein research for scientists. The company developed the Amperia product, designed to be compact, affordable, and accessible for every laboratory bench. Abselion aims to free scientists from tedious manual tasks, allowing them to focus on discovery and innovation. The company's journey began with the RED technology, enabling the creation of its flagship product.
How much funding has Abselion raised?
Abselion has raised a total of $8.4M across 1 funding round:
Series A
$8.4M
Series A (2024): $8.4M with participation from Merck Ventures, BGF, and the Untitled Ventures
Key Investors in Abselion
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, focused on investing in innovative technologies and products that can significantly impact Merck's core business areas. They invest globally in transformational ideas and take an active role in their portfolio companies to drive commercial success, with a strong emphasis on early-stage investing and company creation.
BGF
BGF, headquartered in London, is the most active and influential investor in small and mid-sized businesses in the UK. As an established and independent company, it provides support to a wide range of growing companies across all regions and sectors of the economy, from early stage to quoted businesses.
the Untitled Ventures
the Untitled Ventures is an early growth stage fund specializing in deep tech startups from Eastern Europe. Their mission is to help new technology companies with competitive products and ambitious teams enter the international market, acting as a bridge between Eastern and Western Europe to scale tech companies globally.
What's next for Abselion?
With the recent major strategic investment and a total funding of $8.4M, Abselion is poised for significant expansion. This enterprise-level capital injection is expected to fuel further product development, enhance market penetration, and potentially explore new research avenues. The company's focus on making advanced protein research tools accessible suggests a strategy aimed at democratizing scientific discovery, positioning Abselion as a key player in the life sciences technology sector.
See full Abselion company page
